U.S. Markets closed
  • S&P Futures

    3,702.50
    -6.50 (-0.18%)
     
  • Dow Futures

    29,636.00
    -33.00 (-0.11%)
     
  • Nasdaq Futures

    11,360.25
    -16.50 (-0.15%)
     
  • Russell 2000 Futures

    1,682.90
    -3.20 (-0.19%)
     
  • Crude Oil

    79.72
    +0.98 (+1.24%)
     
  • Gold

    1,650.00
    -5.60 (-0.34%)
     
  • Silver

    18.74
    -0.17 (-0.90%)
     
  • EUR/USD

    0.9684
    -0.0004 (-0.0387%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • Vix

    29.92
    +2.57 (+9.40%)
     
  • GBP/USD

    1.0800
    -0.0057 (-0.5249%)
     
  • USD/JPY

    143.5830
    +0.2630 (+0.1835%)
     
  • BTC-USD

    18,871.20
    -65.11 (-0.34%)
     
  • CMC Crypto 200

    433.59
    -10.95 (-2.46%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    26,680.01
    -473.82 (-1.74%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS

·2 min read

New York, New York--(Newsfile Corp. - April 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information go to:

https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=15324&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

If you suffered a loss in Emergent Bio you have until June 18, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82363.